CTA311 is an investigational ‘ready-at-point of care’ allogeneic anti-CD19 CAR-T cell therapy designed for B-cell mediated disease. The product candidate incorporates T-cell receptor (TCR) and HLA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback